Condition: Tuberous Sclerosis Complex · Sponsor: Katarzyna Kotulska
The purpose of the RaRE-TS study is to determine safety, tolerability and efficacy of rapamycin versus placebo in a drug resistant epilepsy associated with tuberous sclerosis complex (TSC).
This description comes directly from the study's public registry record.
Katarzyna Kotulska-Jozwiak · +48 22 8157404 · k.kotulska@ipczd.pl
Monika Szkop · +48 22 815 74 88 · m.szkop@ipczd.pl
Always discuss trial participation with your own doctor first.
| Medical University of Lodz | Lodz, Poland | Not Yet Recruiting |
| Children's Memorial Health Institute, Neurology and Epileptology | Warsaw, Poland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05534672